Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVT GBS-06 vaccine in women of childbearing age
NCT06611371Phase 2Active, not recruiting
- Sponsor
- Inventprise
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Split/Subunit Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of IVT GBS-06 in group B streptococcal infection (4 arms), sponsored by Inventprise. Primary endpoints: Immediate Adverse Events at 30 minutes, Solicited Local Adverse Events at 7 days and 5 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
IVT GBS-06
03
Conditions
group B streptococcal infection
Beyond the preview
Go deeper on NCT06611371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611371.